Breast Cancer: Suzi's Patient Story

Patient Info: Suzi, Female

Suzi completed lumpectomy, weekly chemotherapy, and radiation and remained on Herceptin every 3 weeks through September 2025. She had not yet been declared to have no evidence of disease.

breastcancer.orgRead more →

Stage IV HER2-Positive Breast Cancer: Leftfootforward's Survivor Story

Patient Info: Leftfootforward, Female, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain | Liver

Leftfootforward was diagnosed with Stage IIB HER2-positive breast cancer in 2010 and metastatic brain/liver disease in 2012; after systemic therapy, Gamma Knife, craniotomy for necrotic tissue, partial liver lobectomy, and resumed Herceptin, her latest scans showed no evidence of disease.

BreastCancer.org (ES)Read more →

Stage II HER2-Positive Breast Cancer: Frédérique's Survivor Story

Patient Info: Frédérique, Female, 40s | Stage II

Biomarkers: HER2-positive

Frédérique was listed as having complete remission after Herceptin/trastuzumab treatment for HER2-positive Stage II breast cancer.

Fondation ARCRead more →

Stage IV HER2-Positive Breast Cancer: Pilar's Patient Story

Patient Info: Pilar, Female, 40s | Stage IV

Biomarkers: Hormone receptor-positive; HER2-positive

Pilar was living with metastatic hormone receptor-positive, HER2-positive breast cancer, continuing systemic treatment with Zoladex, aromatase inhibitors, trastuzumab, and pertuzumab, and managing side effects with rehabilitation support.

Breast Cancer: Greta's Survivor Story

Patient Info: Greta Tietze-Stein, Female, 50s

Greta completed breast-conserving surgery, chemotherapy, radiation, trastuzumab antibody therapy, and hormone therapy, and continued follow-up while managing fear of another finding and rebuilding life around family, faith, and self-care.

Krankheitserfahrungen.deRead more →

How Learning To Ask For Help Can Make Life With MBC Easier

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Not explicitly reported; HER2-targeted treatment with Herceptin and Tykerb reported

Metastatic Site: Brain; liver

Living with Stage IV metastatic breast cancer involving brain and liver; latest scans showed no evidence of disease, and she reported spending most of her Stage IV life in NED status.

breastcancer.orgRead more →

Breast Cancer: Genevieve's Survivor Story

Patient Info: Genevieve, Female, 40s

Biomarkers: 1987 tumor not hormone-receptive; 2017 tumor hormone-receptive. 2022 full marker panel not stated.

After breast cancer episodes beginning in 1987, another tumor in 2017, and cancer found again in 2022, PET scans every 3-4 months were clear and she described herself as in remission again as of May 2025.

breastcancer.orgRead more →

HER2-Positive Breast Cancer: Jim's Patient Story

Patient Info: Jim Keegan, Male, 70+

Biomarkers: HER2-positive; BRCA1/BRCA2 negative

Jim completed surgery, chemotherapy and 1 year of Herceptin for early-stage HER2-positive male breast cancer, then continued tamoxifen and yearly MSK surveillance while advocating for male breast cancer awareness.

Memorial Sloan KetteringRead more →

Stage IV HER2-Positive Breast Cancer: Jennifer's Patient Story

Patient Info: Jennifer Feinberg, Female, 40s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: brain

8+ years after her initial breast cancer diagnosis, she was living with metastatic HER2-positive breast cancer with brain metastases and receiving trastuzumab as her tenth line of treatment.

Dana-FarberRead more →

HER2-positive breast cancer complicated by severe anemia during chemotherapy

Patient Info: Anonymized, female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-positive; germline BRCA1 likely pathogenic mutation

At 4.5-year follow-up, she remained free of breast-cancer recurrence and had no recurrence of the severe treatment-related anemia.

PubMed CentralRead more →

HER2-Positive Breast Cancer Treatment Followed by Multiple Myeloma

Patient Info: Anonymized, female, 50s | Stage II

Biomarkers: ER-negative; PR-negative; HER2 3+; Ki-67 70%

Postoperative imaging showed no breast cancer recurrence or distant metastasis, and the breast cancer was described as stable when a separate multiple myeloma diagnosis was made.

PubMed CentralRead more →

Stage IV HR-Positive Breast Cancer: Alison's Survivor Story

Patient Info: Alison, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-positive

Metastatic Site: Cervical/neck lymph nodes

Alison reported complete remission since August 2017 while continuing intermittent maintenance chemotherapy, most recently 1 month of treatment followed by 2 months off.

The Patient StoryRead more →

Stage III HR-Positive Invasive Ductal Carcinoma: Stefanie's Survivor Story

Patient Info: Stefanie, Female | Stage III

Biomarkers: ER-positive, PR-positive and HER2-positive

Stefanie completed chemotherapy, breast-conserving surgery, prolonged Herceptin and 30 radiation treatments, then moved into survivorship while still adjusting to the lasting effects of treatment.

The Patient StoryRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Shari's Patient Story

Patient Info: Shari S., Female | Stage IV

Biomarkers: ER-positive, PR-positive and HER2-positive; no inherited cancer mutation was identified

Metastatic Site: Brain; other initial metastatic sites were not named

Systemic imaging after chemotherapy showed no active disease, but brain metastases later required stereotactic radiation. Shari remained stage 4, continued Herceptin every 3 weeks and underwent brain MRI every 3–4 months.

The Patient StoryRead more →

Stage III HER2-Positive Breast Cancer: Genoa's Survivor Story

Patient Info: Genoa M., Female | Stage III

Biomarkers: HER2-positive; ER-positive

As of June 2026, Genoa had completed treatment for Stage III HER2-positive, ER-positive breast cancer with neoadjuvant Taxotere/carboplatin/trastuzumab, lumpectomy, and radiation, and was focused on survivorship and rebuilding life after treatment.

The Patient StoryRead more →

Stage IV HER2-Positive Invasive Ductal Carcinoma: Renee's Patient Story

Patient Info: Renee N., Female | Stage IV

Biomarkers: HER2-positive

Metastatic Site: Brain

As of June 2026, Renee’s public story described living with metastatic HER2-positive breast cancer as a chronic illness, after brain radiation and while on Kadcyla every 3 weeks with stable scans reported in December 2019 and early March 2020.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Rach's Patient Story

Patient Info: Rach D., Female, Under 40 | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive

As of June 2026, Rach described Stage II triple-positive breast cancer treated with fertility preservation, 6 rounds of neoadjuvant TCHP including Herceptin, Zoladex ovarian suppression, and double mastectomy with reconstruction.

The Patient StoryRead more →

Breast cancer treatment during pregnancy followed by postpartum targeted therapy

Patient Info: Anonymized, Female, Under 40 | Stage IV

She achieved a near-complete response after 4 cycles of docetaxel and then continued systemic treatment after delivery.

PubMed CentralRead more →

Stage IV triple-negative invasive lobular breast cancer with HER2 mutations: complete metabolic response to trastuzumab deruxtecan

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: Triple-negative invasive lobular breast cancer with HER2-low/dubious staining and HER2 FISH-negative; somatic ERBB2/HER2 and mutations.

Metastatic Site: iliac bone lesions / bone metastases

As of January 2026, metastatic triple-negative invasive lobular breast cancer with HER2 mutations had a sustained complete metabolic response to trastuzumab deruxtecan for 20 months, with dose reduction for neutropenia and no pulmonary toxicity.

PubMed CentralRead more →

Glycogen-rich clear cell breast carcinoma: HER2-positive early-stage case with disease-free follow-up

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: ER-positive; HER2-positive; PR-negative; Ki-67 ~10%; intracytoplasmic glycogen confirmed

At 1-year follow-up, she had no evidence of breast cancer recurrence.

PubMed CentralRead more →

Recurrent breast cancer complicated by T-DXd-associated dermatomyositis and interstitial lung disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Initial tumor had weak ER/AR, PR-negative, HER2 0. Recurrence became ER/PR/AR-negative, HER2-low, PD-L1 CPS ~30.

The cancer progressed after adjuvant therapy and again after 6 cycles of gemcitabine/carboplatin. Trastuzumab deruxtecan was followed by dermatomyositis features and interstitial pneumonia, with symptoms worsening despite glucocorticoid treatment after continued exposure.

PubMed CentralRead more →

HER2-positive breast cancer: brain recurrence, T-DXd liver injury, and later progression

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: HER2-positive; hormone receptor-negative; grade 3 infiltrative breast carcinoma

Metastatic Site: brain; thoracic lymph nodes

As of October 2025, the patient had developed brain and thoracic nodal recurrence after HER2-directed treatment, experienced T-DXd-associated liver injury, progressed after later paclitaxel/trastuzumab, and died at home in December 2024 under palliative care.

PubMed CentralRead more →

Stage IIIB HER2-positive breast cancer followed by resected pancreatic ductal adenocarcinoma

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: Breast cancer HER2-amplified; ER/PR changed from positive to negative after treatment. Pancreatic markers supported a separate pancreatic cancer.

The breast cancer achieved radiological and clinical remission after multimodality HER2-directed treatment. In 2025, a separate pancreatic ductal adenocarcinoma was resected, and adjuvant gemcitabine plus albumin-bound paclitaxel was recommended.

PubMed CentralRead more →

Stage IV HER2-Positive Breast Cancer: Paul's Patient Story

Patient Info: Paul Forgette, Male, 60s | Stage IV

Biomarkers: HER2-positive; triple-positive breast cancer; CHEK2 mutation

Metastatic Site: Bones; lymph nodes

By October 2025, 9 months after starting Enhertu, Paul’s Stage IV HER2-positive male breast cancer was described as dormant, not cured, with continued City of Hope care and integrative support.

City of HopeRead more →